Skip to main navigation
Skip to search
Skip to main content
Amsterdam UMC Home
Help & FAQ
Link opens in a new tab
Search content at Amsterdam UMC
Home
Researchers
Departments & Research Institutes
Projects & Funding
Publications
Datasets
Prizes
Activities
Courses
Cohorts
Press/Media
Impact
Rituximab - Shadow, illusion or light?
Ronald F. van Vollenhoven
pre-AMC
Research output
:
Contribution to journal
›
Review article
›
Academic
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Rituximab - Shadow, illusion or light?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Rituximab
100%
Illusion
100%
Systemic Lupus Erythematosus
57%
Controlled Clinical Trial
14%
Inflammatory Arthritis
14%
Rheumatoid Arthritis
14%
Observational Study
14%
Off-Label Use
14%
CD20 Antibody
14%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Illusion
100%
Systemic Lupus Erythematosus
57%
Controlled Clinical Trial
14%
Rheumatoid Arthritis
14%
Inflammatory Arthritis
14%
Observational Study
14%
Off-Label Use
14%
CD20 Antibody
14%
Immunology and Microbiology
Rituximab
100%
Systemic Lupus Erythematosus
57%
Inflammatory Arthritis
14%
CD20 Antibody
14%
Keyphrases
MabThera
20%
Rituxan
20%